Helus Pharma Announces Co-Founders’ Transition from Executive Leadership as Company Advances Toward Next Stage of Development
Helus Pharma co-founders Eric So and Paul Glavine have stepped down from their executive roles (President/Executive Chairman and Chief Growth Officer, respectively) while remaining on the Board of Directors. Board member Mark Lawson, a director since November 2020, was appointed independent Chair effective immediately, and Eric So was named Chairman Emeritus.
Key figures
- Guidance
- topline data from Phase 3 APPROACH pivotal study of HLP003 in major depressive disorder expected Q4 2026
- Lead asset
- HLP003
- Lead asset stage
- Phase 3, Breakthrough Therapy Designation
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.